News Article

Animal medicines firm completes £35m product deal

17 April 2020

Animal drugs and medicines firm Dechra has completed its acquisition of the worldwide rights of the Mirataz product portfolio from Kindred Biosciences Incorporated for £35m.

The Cheshire firm says the addition of Mirataz “significantly enhances” its portfolio and complements its existing product offering to vets.

Dechra, a listed business, has its manufacturing base in Skipton, North Yorkshire, and its head office in Northwich, Cheshire.

Mirataz is a medication for the management of weight loss in cats, a major problem encountered by vets and owners when treating other underlying medical conditions.

This product was launched in the US in July 2018 by KindredBio and the responsibility for sales in this market will transfer immediately to the Dechra US team.

It has recently been approved in the EU and is expected to be launched in all European markets in the coming months.

Read more at: The Business Desk

We use 'cookies' to ensure that we give you the best experience on our website and if you continue to use this site we will assume that you are happy with this. If you would like to know about 'what a cookie is' and how we look after your data privacy here, follow the 'Learn More' link to read our Privacy Notice.

AcceptLearn More